With Eli Lilly’s acquisition of Mablink and Novartis’ investment in Tagworks, both centering on their innovative linker and conjugation technologies – optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more attractive to ADC developers as they strive for a competitive edge over their peers.

As part of the World ADC Series, the 2nd ADC Linker & Conjugation Summit is the only forum exclusively focused on enhancing your linker and conjugation chemistry. With 100+ attendees ranging from boots-on-the-ground scientists working on improving linker & conjugation chemistries daily, through to more senior directors, this conference is the optimal combination of knowledge sharing and networking.

Leave this summit with the confidence to innovate hydrophilic linkers that help prevent aggregation, enhance stability in linkers & conjugations to ensure tumor targeting and hone site-specific conjugations to guarantee homogenous DAR, all to ultimately ensure ADC stability and widen therapeutic index.